Cardiac conditions such as heart failure, stroke, and artery disease are major killers across the globe. Lowering blood sugar levels has been the focus for many years for diabetic patients, but new diabetes medications known as GLP-1 receptor agonists (GLP1Ra) appear to benefit the heart as well. Researchers wanted to know how.
Novo Nordisk is phasing out Human Mixtard, India’s largest-selling insulin brand, along with other pen-based insulin products like Actrapid, Insulatard, and Xultophy. This decision is part of a global move to discontinue older generation insulin products and shift focus to newer, high-profit therapies.
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder with rising global prevalence and limited curative treatments. Through genetic integration using Mendelian randomization (MR) and genome-wide association studies (GWAS), 42 protein-coding genes were identified as being significantly associated with T2DM. Of these, six genes – CLSTN1, KCNJ11, MLX, DLD, RELA, and ULK1—shared common causal variants with the disease, indicating potential as drug targets.
The research investigated the association of the Neutrophil Percentage-to-Albumin Ratio (NPAR) with mortality risk in diabetes or prediabetes patients. NPAR is a metric that reflects both inflammation, as presented in neutrophils, and nutrition, as presented in albumin. The researchers had 6,080 American adults with diabetes or prediabetes data, obtained between 2001 and 2018, via the National Health and Nutrition Examination Survey (NHANES). The population was followed up for a total of 53,217 person-years over which 1,378 deaths occurred, 476 from cardiovascular disease.
US pharma giant Eli Lilly has launched its highly anticipated diabetes and obesity drug, Mounjaro (tirzepatide), in India. The drug, available in 2.5 mg and 5 mg single-dose vials, is priced at ₹3,500 and ₹4,375, respectively. Since it is taken once a week, the monthly cost ranges from ₹14,000 to ₹17,500, significantly lower than the $1,000–$1,200 (₹86,000–1 lakh) price in the US.
The present study sought to establish how much type 2 diabetics manage their blood glucose and what influences their control. It was conducted at Dessie Hospital, Ethiopia, from February to March 2023 among 465 diabetic patients. The HbA1c test, which provides a long-term estimate of blood glucose levels, was used by the researchers rather than relying on fasting blood glucose alone.
